Pomalidomide in combination with dexamethasone approved for use in refractory multiple myeloma

被引：0
|
作者：
Brown, Emily
机构：
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2013年 / 2卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：516 / 517
页数：2
相关论文
共 50 条
  • [1] Pomalidomide in combination with dexamethasone approved for use in refractory multiple myeloma
    Brown, Emily
    FUTURE ONCOLOGY, 2013, 9 (11) : 1684 - 1685
  • [2] Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma
    Hussain, M. Junaid
    Robinson, Myra M.
    Hamadeh, Issam
    Arnall, Justin
    Bhutani, Manisha
    Atrash, Shebli
    Friend, Reed
    Pineda-Roman, Mauricio
    Symanowski, James T.
    Usmani, Saad Z.
    Voorhees, Peter M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (01) : 140 - 144
  • [3] Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)
    Badros, Ashraf Z.
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander M.
    Rapoport, Aaron P.
    Kocoglu, Mehmet H.
    Lederer, Emily
    Philip, Sunita
    Lesho, Patricia
    Johnson, Ashlee
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2016, 128 (22)
  • [4] Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Schlossman, Robert L.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Reimonn, Cassandra A.
    Andrade, Danielle X.
    Redd, Robert
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD ADVANCES, 2025, 9 (05) : 1163 - 1170
  • [5] Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
    Matsue, Kosei
    Iwasaki, Hiromi
    Chou, Takaaki
    Tobinai, Kensei
    Sunami, Kazutaka
    Ogawa, Yoshiaki
    Kurihara, Mari
    Midorikawa, Shuichi
    Zaki, Mohamed
    Doerr, Thomas
    Iida, Shinsuke
    CANCER SCIENCE, 2015, 106 (11): : 1561 - 1567
  • [6] Combination of ixazomib, pomalidomide and dexamethasone in the treatment of multiple myeloma in relapse and refractory to lenalidomide
    Stocker, Nicolas
    HEMATOLOGIE, 2018, 24 (04): : 261 - 262
  • [7] The Combination of Isatuximab with Pomalidomide and Dexamethasone in Second Line Relapse and Refractory Multiple Myeloma
    Bobin, Arthur
    Soufyane, Ennebet
    Guidez, Stephanie
    Chacon, Aurelia
    Gardeney, Helene
    Basle, Caroline
    Dindinaud, Elodie
    Douma, Soukaina
    Roul, Christophe
    Corby, Anne
    Motard, Carine
    Olivier, Gaelle
    Denis, Guillaume
    Vinson, Camille
    Tomowiak, Cecile
    Gruchet, Cecile
    Moya, Niels
    Mocquot, Pauline
    Dessane, Berangere
    Boscagli, Annick
    Perrot, Aurore
    Leleu, Xavier
    BLOOD, 2024, 144 : 7041 - 7042
  • [8] Pomalidomide-dexamethasone combination is efficient in lenalidomide-refractory multiple myeloma
    Coman, Tereza
    HEMATOLOGIE, 2010, 16 (06): : 410 - 411
  • [9] Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma
    Wilson, Lilly
    Cohen, Adam D.
    Weiss, Brendan M.
    Vogl, Dan T.
    Garfall, Alfred L.
    Capozzi, Donna L.
    Mangan, Patricia
    Sanchez, Mary
    Erb, Colleen
    Stadtmauer, Edward
    BLOOD, 2016, 128 (22)
  • [10] Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
    Dharshan Sivaraj
    Michael M Green
    Yubin Kang
    Gwynn D Long
    David A Rizzieri
    Zhiguo Li
    Anderson H Garrett
    Jackie L McIntyre
    Nelson J Chao
    Cristina Gasparetto
    Blood Cancer Journal, 8
12345